EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis

Fengping Peng, Yu Gao iD, Ziqi Zhang iD, Ling Deng, Honglei Liu, Xiaowei Liang, Chunyan Liu iD, Rong Fu iD

Journal of Clinical Laboratory Analysis · 2026

DOI: 10.1002/jcla.70384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2026. Verfasst von Fengping Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Naphthoquinones, Apoptosis, Multiple Myeloma, AMP-Activated Protein Kinases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Education Commission Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma (MM) is an incurable plasma malignancy. Pyruvate kinase M2 (PKM2), a rate‐limiting enzyme in glycolysis, is involved in the metabolic reprogramming of tumors. Shikonin, a natural compound, exhibits anticancer potential. However, whether modulating PKM2 with shikonin can be used as an adjuvant chemotherapeutic strategy for MM remains to be elucidated. We explored the effects of shikonin on the metabolic pathways in MM cells.

Methods

Apoptosis, reactive oxygen species (ROS) production, and cell cycle progression in MM cells treated with shikonin were analyzed using flow cytometry. Shikonin‐treated MM cells were sent for Metabolomics by RNA sequencing and LC–MS/MS metabolomics. The involved signaling pathways were validated using western blotting.

Results

The coMMpass cohort analysis has indicated that high PKM2 expression was related to poor survival of MM cells. Shikonin induced dose‐dependently apoptosis, elevated ROS levels, and cell cycle arrest in G1 phase in MM cells. Multi‐omics analysis revealed 2043 differentially expressed genes and 93 altered metabolites in shikonin‐treated MM cells. Shikonin downregulated the expression of PKM2 and therefore reduced pyruvate/AMP levels and impaired glycolysis. Integrated omics analysis identified AMPK signaling as the common enriched pathway. WB confirmed that shikonin suppressed the expression of PKM2 and GLUT4 and activated the expression of P‐AMPK/PGC1α, indicating the dysregulation of the PKM2‐AMPK‐PGC1α axis.

Conclusion

Shikonin exerts anti‐tumor effects in MM cells by inhibiting PKM2 expression, disrupting glycolytic flux, activating AMPK/PGC1α‐mediated metabolic stress, and triggering the apoptosis process. Inhibition of PKM2 with shikonin is a promising metabolic intervention strategy for MM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesApoptosisMultiple MyelomaAMP-Activated Protein KinasesThyroid HormonesCarrier ProteinsMembrane ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaHumansThyroid Hormone-Binding ProteinsCell Line, TumorSignal TransductionReactive Oxygen SpeciesGene Expression Regulation, NeoplasticMetabolic Reprogramming

Stichwörter der Autor:innen

PKM2PKM2‐AMPK‐PGC1α pathwaymetabolic reprogrammingmultiple myelomashikonin

Substanzen

shikoninNaphthoquinonesThyroid Hormone-Binding ProteinsAMP-Activated Protein KinasesThyroid HormonesCarrier ProteinsMembrane ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, China.
  • Tianjin Institute of Hematology, Tianjin, China.
  • College of Science and Technology, Hebei Agricultural University, Baoding, China.

ORCID-Profile: Yu Gao, Ziqi Zhang, Chunyan Liu, Rong Fu

Förderung

  • Tianjin Education Commission Research Project

Zitieren

APA

Peng, F., Gao, Y., Zhang, Z., Deng, L., Liu, H., Liang, X., Liu, C., & Fu, R. (2026). Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70384

Vancouver

Peng F, Gao Y, Zhang Z, Deng L, Liu H, Liang X, et al. Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70384

BibTeX
@article{Peng2026,
  author = {Peng, Fengping and Gao, Yu and Zhang, Ziqi and Deng, Ling and Liu, Honglei and Liang, Xiaowei and Liu, Chunyan and Fu, Rong},
  title = {Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2026},
  doi = {10.1002/jcla.70384}
}
Kostenlos starten →